

Applied Pediatric Genome Analysis

05 March 2018

Wyeth W. Wasserman
University of British Columbia
BC Children's Hospital

Let's learn the alphabet!



- Technology shifting in clinical genome analysis
- Introduction via case studies
- Almost no statistics

OLD TECHNOLOGY FOR GENOME ANALYSIS: KARYOTYPING




HOW DOES YOUR GENOME DIFFER FROM THE REFERENCE GENOME

- structural variants (impacting ~20Mbp)
 - ~1,000 large deletions
 - ~160 copy-number variants
 - ~1100 “repeat” insertions (Alu, L1, etc)
 - ~4 NUMTs (mitochondria genome)
 - ~10 inversions
- Base-level
 - ~3.5M (~4.5M for AFR) single nucleotide variants
 - Only ~60,000 (~150k) extremely rare (<0.5%)
 - ~0.5M small indels


- Single Nucleotide Polymorphism vs Single Nucleotide Variant
- All SNPs are SNVs, but not all SNVs are SNPs
- SNP refers to a polymorphic variant – a variant that occurs over a specified percentage in a specified population (usually 1% at present)
- Do not say “SNP” unless you mean SNP

Infinium Assays


Infinium I probe design



Infinium II probe design




- Population Determination
- GWAS
- Linkage Analysis
- Clinical MicroArray for Copy Number changes




https://upload.wikimedia.org/wikipedia/commons/thumb/1/12/Manhattan_Plot.png/819px-Manhattan_Plot.png

Pedigree-based Linkage Analysis




EXAMPLE OF LOD SCORES



https://www.researchgate.net/figure/Genome-wide-linkage-analysis-of-the-pedigree-using-affected-members-only-with-10K-A_fig4_38055346


Chromosomal MicroArrays




Chromosomal Microarrays are the clinical standard for detecting copy number variants. They have reliable sensitivity down to ~100,000bp (and pretty good down to ~20,000).

https://www.researchgate.net/figure/Microarray-based-copy-number-analysis-performed-with-the-Affymetrix-Cytogenetics_fig2_275363431

- Until recently the cost of WGS was prohibitive and most individual patients were analyzed for a restricted portion of the genome – the exons.
- “Exomes” recover ~5%
- Different companies offer distinct “kits” which contain oligonucleotides designed to hybridize to the regions of the genome specified by the kit designers




Nature Reviews | **Genetics**



Genotype Calling

Short reads aligned



2 A / 4 G = A/G genotype

Most research grade sequencing studies produce an average of 30-100 reads per position with enormous variance across positions

Whole Exome Sequencing EXAMPLE CASE

- 2 affected siblings & unaffected parents
- Agilent SureSelect kit & Illumina HiSeq 2000 (Perkin-Elmer, USA)
- 5.2 billion 100bp pair-end reads
- coverage per base 32X
- Bowtie, BWA and GSNAP: to map reads to hg19 reference genome
- 99% classified as common variants
- 7 candidate genes
(4 homozygous & 3 compound heterozygous mutations)
- only 1 variant predicted disruptive to protein function
(Sift and PolyPhen2)

CA5A gene: homozygous S233P mutation


(A) CA5A: chr16:87,921,625-87,970,112



(B) chr16:87,925,453-87,925,509

Human	S	E	T	L	P	P	T	T	L	S	G	A	Y	T	W	Y	D	W	C
Rhesus	S	E	T	L	P	P	T	T	L	S	G	A	Y	T	W	Y	D	R	C
Mouse	S	E	A	L	P	P	T	T	L	S	G	P	Y	T	W	Y	D	R	C
Rabbit	S	E	A	L	P	P	T	T	L	S	G	G	Y	T	W	Y	D	R	C
Dog	S	E	T	L	P	P	T	T	L	S	G	P	Y	T	W	Y	D	R	C
Elephant	S	E	T	L	P	P	T	T	L	S	G	P	Y	T	W	Y	D	P	C
Opossum	S	E	T	L	P	P	T	T	L	S	G	G	Y	T	W	Y	D	Q	C
X_tropicalis	S	E	T	L	P	P	T	T	L	S	G	S	Y	T	W	Y	D	G	C
Lamprey	T	E	Y	P	P	P	T	T	L	S	G	P	Y	T	W	F	D	L	C

(C)



chr16:87,925,471-87,925,494


WT: GGT GGT GAG CGA GCC CGC GTA GGT


S

MT: GGT GGT GAG CGG GCC CGC GTA GGT

P

(D)





Patient Selection

- ID or at risk for ID
- Biochemical phenotype
- oaCGH negative
- Known genes not mutated

Patient Consent

- TIDEX de-identification study numbers

Sample collection

- Blood/saliva/urine

Sequencing

- DNA prep; WES + WGS

Bioinformatics analysis

- Alignment
- Variant calls
- Variant filtering
- **Variant-phenotype link interpretation**

Candidate Lists to clinicians

Sanger

- Sanger re-sequencing

Experimental

- Experimental, fibroblasts, model organisms, etc.

OMICS2TREATID
case presentation form

Family number: Family descriptor:

Physician
Name: Institution:
Email:
Phone number: Date:

Clinical information
Index Patient(s): ☐ male ☐ female Age:
On delay / Intel disk: ☐ Yes ☐ No security:
Present clinical symptoms:

Laboratory info
Biochemical abnormalities (sample, profile):
Neuro-imaging performed (results):
Single gene tests (list all genes & results):
Mitochondrial DNA / nuclear genes (list all genes & results):
Other relevant (abnormal) investigations:

Family history
Consanguinity: ☐ Yes ☐ No
Draw or attach pedigree (include study number):

Inclusion Criteria met?
☐ Link w/ ID / ID ☐ Built analysis (consanguinity only)
☐ Abnormal biochemical phenotype ☐ Chance of gene discovery
☐ TIDEX test tier, urine oligoGAGs, TIDEX, full acids performed ☐ Feasibility
☐ Chromosome micro-array normal ☐ Yes DNA available
☐ Mitochond DNA normal ☐ Family motivated?


TIDEX score:
Candidate gene / pathway hypothesis:

Family consented: ☐ Yes ☐ No By: Thomas ☐ Sapon

Sample availability for each family member (list study numbers)
DNA available: ☐ Yes ☐ No Study #:
2x Serum available: ☐ Yes ☐ No Study #:
2x urine available: ☐ Yes ☐ No Study #:
Urine available: ☐ Yes ☐ No Study #:
CSF available: ☐ Yes ☐ No Study #:
Medications (when samples drawn):
Special Diet (when samples drawn):
MESH terms proposed for bio-informatics:
Other:

- Cost no longer prohibitive
- The FEDEX moment is approaching
- WGS has many advantages
 - Copy number calling
 - Structural changes
 - No capture bias
 - Splice altering events in introns
 - Distal regulatory regions

From Critical Region to Mutations



WGS: Reveals shared ~8MB region with
no protein coding alterations

- 5 Mbp critical region
- 30 rare variants
- No protein altering variants
- Two genes nearby with potential causal roles
- Ongoing

- Reliable CNV equivalent to CMA
- Detection of balanced translocations
- Phenotype-to-genotype relationship detection
- Accounting for patient population in the analysis
- Phasing

- WGS has arrived
- Cost is decreasing
- Patients increasingly likely to be diagnosed for simple genetic disorders

Thank You

